Tremfya FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved July 13, 2017)
Brand name: Tremfya
Generic name: guselkumab
Dosage form: Injection
Company: Janssen Biotech, Inc.
Treatment for: Plaque Psoriasis, Psoriatic Arthritis
Tremfya (guselkumab) is an interleukin-23 blocker indicated for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis in adults.
Development timeline for Tremfya
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.